• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗体介导的排斥反应的发生率与年龄相关,在肾移植后晚期达到平台期,并且在老年受者中对移植物丢失的贡献较小。

The Incidence of Antibody-Mediated Rejection Is Age-Related, Plateaus Late After Kidney Transplantation, and Contributes Little to Graft Loss in the Older Recipients.

机构信息

Rotterdam Transplantation Institute, Department of Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, Netherlands.

出版信息

Transpl Int. 2023 Dec 22;36:11751. doi: 10.3389/ti.2023.11751. eCollection 2023.

DOI:10.3389/ti.2023.11751
PMID:38188697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10768842/
Abstract

It is not known whether antibody-mediated rejection (ABMR) is age-related, whether it plateaus late after transplantation, and to what extent it contributes to graft loss in older recipients. Patients transplanted between 2010 and 2015 ( = 1,054) in a single center had regular follow-up until January 2023. Recipients were divided into age groups at transplantation: 18-39 years ("young"), 40-55 years ("middle age"), and >55 years ("elderly"). Ten years after transplantation the cumulative % of recipients with ABMR was 17% in young, 15% in middle age, and 12% in elderly recipients ( < 0.001). The cumulative incidence of ABMR increased over time and plateaued 8-10 years after transplantation. In the elderly, with a median follow-up of 7.5 years, on average 30% of the recipients with ABMR died with a functional graft and ABMR contributed only 4% to overall graft loss in this group. These results were cross-validated in a cohort of recipients with >15 years follow-up. Multivariate cox-regression analysis showed that increasing recipient age was independently associated with decreasing risk for ABMR. In conclusion, the cumulative risk for ABMR is age-dependent, plateaus late after transplantation, and contributes little to overall graft loss in older recipients.

摘要

目前尚不清楚抗体介导的排斥反应(ABMR)是否与年龄有关,它是否在移植后晚期趋于稳定,以及在多大程度上导致老年受者的移植物丢失。在一个中心,2010 年至 2015 年间接受移植的患者(=1054 例)接受了定期随访,直至 2023 年 1 月。受者在移植时分为年龄组:18-39 岁(“年轻”)、40-55 岁(“中年”)和>55 岁(“老年”)。移植后 10 年,年轻、中年和老年受者中 ABMR 的累积发生率分别为 17%、15%和 12%(<0.001)。ABMR 的累积发生率随时间增加,并在移植后 8-10 年趋于稳定。在中位随访时间为 7.5 年的老年患者中,ABMR 患者中有 30%平均死于功能移植物,ABMR 仅导致该组患者整体移植物丢失的 4%。这些结果在具有 >15 年随访的受者队列中得到了交叉验证。多变量 Cox 回归分析显示,受者年龄的增加与 ABMR 风险的降低独立相关。总之,ABMR 的累积风险与年龄有关,在移植后晚期趋于稳定,并且在老年受者中对整体移植物丢失的贡献很小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e08c/10768842/ab2ae648c79c/ti-36-11751-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e08c/10768842/911dc3a2c1f3/ti-36-11751-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e08c/10768842/4eb33539518b/ti-36-11751-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e08c/10768842/341a0f0d8398/ti-36-11751-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e08c/10768842/2a72221711b0/ti-36-11751-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e08c/10768842/ab2ae648c79c/ti-36-11751-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e08c/10768842/911dc3a2c1f3/ti-36-11751-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e08c/10768842/4eb33539518b/ti-36-11751-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e08c/10768842/341a0f0d8398/ti-36-11751-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e08c/10768842/2a72221711b0/ti-36-11751-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e08c/10768842/ab2ae648c79c/ti-36-11751-g005.jpg

相似文献

1
The Incidence of Antibody-Mediated Rejection Is Age-Related, Plateaus Late After Kidney Transplantation, and Contributes Little to Graft Loss in the Older Recipients.抗体介导的排斥反应的发生率与年龄相关,在肾移植后晚期达到平台期,并且在老年受者中对移植物丢失的贡献较小。
Transpl Int. 2023 Dec 22;36:11751. doi: 10.3389/ti.2023.11751. eCollection 2023.
2
Causes of Kidney Graft Failure in a Cohort of Recipients With a Very Long-Time Follow-Up After Transplantation.一组移植后长期随访受者肾移植失败的原因
Front Med (Lausanne). 2022 Jun 6;9:842419. doi: 10.3389/fmed.2022.842419. eCollection 2022.
3
Antibody-mediated rejection in the Banff classifications of 2007 and 2017: A comparison of renal graft loss prediction capability.2007年和2017年班夫分类中的抗体介导性排斥反应:肾移植丢失预测能力的比较。
Transpl Immunol. 2018 Dec;51:40-44. doi: 10.1016/j.trim.2018.08.008. Epub 2018 Aug 29.
4
Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.移植后1年的亚临床排斥反应表型与同种异体肾移植的结局
J Am Soc Nephrol. 2015 Jul;26(7):1721-31. doi: 10.1681/ASN.2014040399. Epub 2015 Jan 2.
5
Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.跨越供者特异性抗体屏障的死亡供者肾移植:抗体介导排斥反应的预测因素
Nephrol Dial Transplant. 2016 Aug;31(8):1342-51. doi: 10.1093/ndt/gfw027. Epub 2016 Mar 24.
6
Early versus late acute antibody-mediated rejection in renal transplant recipients.肾移植受者的早期与晚期急性抗体介导的排斥反应。
Transplantation. 2013 Jul 15;96(1):79-84. doi: 10.1097/TP.0b013e31829434d4.
7
B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients.B细胞活化因子,肾移植受者抗体介导排斥反应的一个预测指标。
Nephrology (Carlton). 2018 Feb;23(2):169-174. doi: 10.1111/nep.12972.
8
C3d-binding Donor-specific HLA Antibody Is Associated With a High Risk of Antibody-mediated Rejection and Graft Loss in Stable Kidney Transplant Recipients: A Single-center Cohort Study.C3d结合供者特异性HLA抗体与稳定肾移植受者抗体介导的排斥反应及移植物丢失高风险相关:一项单中心队列研究
Transplant Proc. 2018 Dec;50(10):3452-3459. doi: 10.1016/j.transproceed.2018.06.037. Epub 2018 Jul 2.
9
Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.在一项针对肾移植受者的大型前瞻性横断面研究中晚期抗体介导的排斥反应——BORTEJECT试验筛查阶段的初步结果
Clin Transpl. 2014:189-95.
10
Single antigen testing to reduce early antibody-mediated rejection risk in female recipients of a spousal donor kidney.单抗原检测以降低配偶供肾女性受者早期抗体介导排斥反应的风险
Transpl Immunol. 2021 Aug;67:101407. doi: 10.1016/j.trim.2021.101407. Epub 2021 May 8.

引用本文的文献

1
Antibody-mediated rejection-treatment standard.抗体介导的排斥反应治疗标准。
Nephrol Dial Transplant. 2025 Aug 1;40(8):1615-1627. doi: 10.1093/ndt/gfaf097.
2
Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression.在接受他克莫司/霉酚酸酯/类固醇维持免疫抑制治疗、免疫风险较低的肾移植受者中,巴利昔单抗与无诱导治疗的比较
J Clin Med. 2024 Oct 16;13(20):6151. doi: 10.3390/jcm13206151.

本文引用的文献

1
The detrimental effect of donor-specific antibodies is irrespective of its level in highly-immunized living donor kidney transplant recipients: A case-control series.供者特异性抗体的有害影响与其在高度免疫的活体供肾移植受者中的水平无关:一项病例对照系列研究。
Front Immunol. 2023 Jan 10;13:1093359. doi: 10.3389/fimmu.2022.1093359. eCollection 2022.
2
Tacrolimus Monotherapy is Safe in Immunologically Low-Risk Kidney Transplant Recipients: A Randomized-Controlled Pilot Study.他克莫司单药治疗在免疫低危肾移植受者中是安全的:一项随机对照的初步研究。
Transpl Int. 2022 Oct 24;35:10839. doi: 10.3389/ti.2022.10839. eCollection 2022.
3
The natural history of donor-specific HLA antibodies after kidney transplantation.
肾移植后供体特异性HLA抗体的自然病程。
Front Med (Lausanne). 2022 Sep 16;9:943502. doi: 10.3389/fmed.2022.943502. eCollection 2022.
4
Progressive Loss of Donor-Reactive CD4 Effector Memory T Cells due to Apoptosis Underlies Donor-Specific Hyporesponsiveness in Stable Renal Transplant Recipients.稳定期肾移植受者中由于凋亡导致供者反应性 CD4 效应记忆 T 细胞渐进性丧失是供者特异性低反应性的基础。
J Immunol. 2022 Oct 1;209(7):1389-1400. doi: 10.4049/jimmunol.2200352. Epub 2022 Sep 2.
5
Causes of Kidney Graft Failure in a Cohort of Recipients With a Very Long-Time Follow-Up After Transplantation.一组移植后长期随访受者肾移植失败的原因
Front Med (Lausanne). 2022 Jun 6;9:842419. doi: 10.3389/fmed.2022.842419. eCollection 2022.
6
Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change.老年受试者的免疫衰老与疫苗效力改变:一个难以改变的误解
Vaccines (Basel). 2022 Apr 13;10(4):607. doi: 10.3390/vaccines10040607.
7
COVID-19 Vaccination Response in Kidney Transplant Recipients With and Without Mycophenolate Mofetil: Follow-up of a Randomized Controlled Trial.接受与未接受吗替麦考酚酯的肾移植受者对COVID-19疫苗的反应:一项随机对照试验的随访
Kidney Int Rep. 2022 Jun;7(6):1433-1434. doi: 10.1016/j.ekir.2022.04.002. Epub 2022 Apr 7.
8
Effect of Early Steroid Withdrawal on Posttransplant Diabetes Among Kidney Transplant Recipients Differs by Recipient Age.早期停用类固醇对肾移植受者移植后糖尿病的影响因受者年龄而异。
Transplant Direct. 2021 Dec 13;8(1):e1260. doi: 10.1097/TXD.0000000000001260. eCollection 2022 Jan.
9
ABO-incompatible kidney transplantation in perspective of deceased donor transplantation and induction strategies: a propensity-matched analysis.从已故供体移植和诱导策略的角度来看 ABO 不相容的肾移植:一项倾向评分匹配分析。
Transpl Int. 2021 Dec;34(12):2706-2719. doi: 10.1111/tri.14145. Epub 2021 Nov 11.
10
Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys.阿仑单抗作为移植肾晚期抗体介导排斥反应的二线治疗药物。
Transplant Proc. 2021 Sep;53(7):2206-2211. doi: 10.1016/j.transproceed.2021.07.005. Epub 2021 Aug 8.